19/12/2022 Review of cancer drugs for prostate cancer
The Ministry of Health’s Drug Advisory Committee has recommended:
- Degarelix 80 mg and 120 mg injections;
- Enzalutamide 40 mg capsule; and
- Olaparib 100 mg and 150 mg tablets
for treating prostate cancer in line with specific clinical criteria.
Subsidy status
RDegarelix 80 mg and 120 mg injections are recommended for inclusion on the Medication Assistance Fund (MAF) for treating advanced hormone-dependent prostate cancer with effect from 4 January 2022.
REnzalutamide 40 mg capsule, in combination with androgen deprivation therapy (ADT) is recommended for inclusion on MAF with effect from 1 September 2022 for treating:
- high-risk non-metastatic castration-resistant prostate cancer (nmCRPC);
- metastatic hormone-sensitive prostate cancer (mHSPC); and
- metastatic castration-resistant prostate cancer (mCRPC).
ROlaparib 100 mg and 150 mg tablets are recommended for inclusion on MAF with effect from 1 September 2022, for treating patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene BRCA1/2 and/or ATM-mutations (germline and/or somatic) whose disease has progressed following prior treatment with abiraterone or a second-generation anti-androgen. Androgen deprivation therapy (ADT) should be continued.
NRMAF assistance does not apply to apalutamide 60 mg tablet, darolutamide 300 mg tablet, olaparib 50 mg capsule or cabazitaxel 60 mg/1.5 mL injection for the treatment of prostate cancer.
Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.